riluzole and ketamine
riluzole has been researched along with ketamine in 20 studies
Research
Studies (20)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chéramy, A; Desmonts, JM; Glowinski, J; Mantz, J; Thierry, AM | 1 |
| Bansinath, M; Nivarthi, RN; Turndorf, H | 1 |
| Miyamoto, KJ; Miyamoto, TA | 1 |
| Bodewits, P; de Haan, P; Dzoljic, M; Jacobs, MJ; Kalkman, CJ; Lips, J; Vanicky, I | 1 |
| Keegan, K; Mathew, SJ; Smith, L | 1 |
| Howland, RH | 1 |
| aan het Rot, M; Charney, DS; Collins, KA; Mathew, SJ; Murrough, JW; Reich, DL | 1 |
| Machado-Vieira, R; Manji, HK; Zarate, CA | 1 |
| Deuschle, M; Gass, P; Paslakis, G | 1 |
| Brutsche, N; Diazgranados, N; Franco-Chaves, J; Henter, ID; Ibrahim, L; Kronstein, P; Luckenbaugh, DA; Manji, HK; Moaddel, R; Wainer, I; Zarate, CA | 1 |
| Brutsche, N; Duncan, WC; Ferrarelli, F; Hejazi, NS; Manji, HK; Riedner, BA; Sarasso, S; Selter, J; Tononi, G; Yuan, P; Zarate, CA | 1 |
| Owen, RT | 1 |
| Ballard, ED; Brutsche, NE; Furey, ML; Ionescu, DF; Luckenbaugh, DA; Niciu, MJ; Richards, EM; Vande Voort, JL; Zarate, CA | 2 |
| Brocco, M; Cangelosi, A; Fernandez-Miyakawa, ME; Geoghegan, P; Goldstein, J; Loidl, FC; Morris, WE; Redondo, LM | 1 |
| Wang, G; Wang, H; Wu, C; Yao, R; Yuan, M | 1 |
Reviews
7 review(s) available for riluzole and ketamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Glutamate modulators as novel interventions for mood disorders.
Topics: Animals; Antidepressive Agents; Excitatory Amino Acid Antagonists; Humans; Ketamine; Mood Disorders; Neural Pathways; Neuronal Plasticity; Receptors, AMPA; Riluzole; Synaptic Transmission | 2005 |
Glutamate-modulating drugs & the treatment of mental disorders.
Topics: Acamprosate; Amantadine; Cycloserine; Glutamic Acid; Humans; Ketamine; Lamotrigine; Memantine; Mental Disorders; Psychotropic Drugs; Riluzole; Taurine; Triazines | 2007 |
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
Topics: Animals; Brain; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Ketamine; Mood Disorders; Neuroglia; Receptors, Glutamate; Riluzole; Synapses | 2009 |
[The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data].
Topics: Animals; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Ketamine; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Riluzole; Stress, Psychological | 2011 |
Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Glutamine; Humans; Ketamine; Memantine; Riluzole; Treatment Outcome | 2012 |
Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Humans; Ketamine; Male; Middle Aged; Randomized Controlled Trials as Topic; Riluzole; Treatment Outcome | 2020 |
Trials
5 trial(s) available for riluzole and ketamine
| Article | Year |
|---|---|
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
Topics: Adult; Aged; Depression; Drug Interactions; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Hallucinogens; Humans; Injections, Intravenous; Ketamine; Lamotrigine; Male; Middle Aged; Pilot Projects; Placebos; Riluzole; Secondary Prevention; Time Factors; Treatment Outcome; Triazines | 2010 |
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Depression; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Ketamine; Male; Middle Aged; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Riluzole; Time Factors; Young Adult | 2012 |
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.
Topics: Adult; Analysis of Variance; Brain Waves; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Electroencephalography; Enzyme-Linked Immunosorbent Assay; Excitatory Amino Acid Antagonists; Female; Humans; Ketamine; Male; Middle Aged; Psychiatric Status Rating Scales; Riluzole; Single-Blind Method; Sleep Stages; Statistics as Topic; Time Factors | 2013 |
Riluzole likely lacks antidepressant efficacy in ketamine non-responders.
Topics: Adult; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Female; Follow-Up Studies; Humans; Ketamine; Male; Middle Aged; Riluzole; Treatment Outcome | 2014 |
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Topics: Adolescent; Adult; Aged; Alcohol-Related Disorders; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Excitatory Amino Acid Antagonists; Family; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Ketamine; Middle Aged; Riluzole; Treatment Outcome; Young Adult | 2014 |
Other Studies
8 other study(ies) available for riluzole and ketamine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Anesthetic properties of riluzole (54274 RP), a new inhibitor of glutamate neurotransmission.
Topics: Anesthetics; Animals; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Glutamic Acid; Injections, Intraperitoneal; Ketamine; Male; Rats; Rats, Inbred Strains; Reflex, Abnormal; Riluzole; Sleep; Synaptic Transmission; Thiazoles; Thiopental | 1992 |
Role of nitric oxide-mediated signal transduction in hypothermia induced by intravenous anesthetics.
Topics: Anesthetics, Intravenous; Animals; Cerebellum; Cyclic GMP; Hypothermia; Ketamine; Mice; Nitric Oxide; Nitric Oxide Synthase; Pentobarbital; Proto-Oncogene Proteins c-fos; Riluzole; Signal Transduction; Thiazoles | 1997 |
A word of caution in extrapolating the riluzole spinal cord injury protective effects obtained in a rabbit model under ketamine anesthesia.
Topics: Anesthetics, Dissociative; Animals; Cardiopulmonary Bypass; Disease Models, Animal; Drug Synergism; Excitatory Amino Acid Antagonists; Follow-Up Studies; Ischemia; Ketamine; Neurologic Examination; Neuroprotective Agents; Rabbits; Riluzole; Spinal Cord | 1999 |
Neuroprotective effects of riluzole and ketamine during transient spinal cord ischemia in the rabbit.
Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Infarction; Ketamine; Neuroprotective Agents; Paraplegia; Rabbits; Riluzole; Spinal Cord; Spinal Cord Ischemia | 2000 |
Clostridium perfringens epsilon toxin induces permanent neuronal degeneration and behavioral changes.
Topics: Animals; Apoptosis; Bacterial Toxins; Behavior, Animal; Brain; Cerebral Cortex; Corpus Striatum; Demyelinating Diseases; Dexamethasone; Female; Hippocampus; Hypothalamus; Intermediate Filaments; Ketamine; Lethal Dose 50; Male; Mice; Neurons; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Reserpine; Riluzole; Synapses | 2017 |